Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.28 USD 0.24 ( 23.08%)
Last update at 2026-11-06T21:00:00Z
VOLUME
164388
Market Cap
50.94M

Momentum Score

…

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.08
Low
1.37
High
52 Week Price Range
1.50
Low
9.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Dogwood Therapeutics is a clinical-stage biopharmaceutical company developing therapies to regenerate heart tissue by targeting cellular repair pathways. Long-term growth may be driven by large unmet need in heart failure, its differentiated regenerative approach, and advancement of its development pipeline and partnerships.
Principal risks are high clinical and regulatory uncertainty for novel regenerative therapies, an early-stage unprofitable profile with potential financing needs, and competition from established cardiovascular developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.04
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-49.23%
Net Debt
-6.36M
ROCE
-32.11%
Diluted EPS TTM
-7.13

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -34.04M -12.35M -5.30M -12.25M -15.96M
Net income -34.26M -12.35M -5.30M -12.25M -15.96M
Selling general administrative 6.10M 8.70M 3.72M 4.25M 4.85M
Gross profit - -0.01M - - -
Reconciled depreciation 0.00M 0.01M 0.00M - -
Ebit -27.97M -12.26M -5.45M -12.32M -15.64M
Ebitda -27.97M -12.25M -5.45M -12.32M -15.64M
Depreciation and amortization 0.00M 0.01M - - -
Operating income -27.97M -12.23M -5.45M -12.32M -15.64M
Other operating expenses 27.97M 12.23M 5.45M 12.32M 15.64M
Interest expense - 0.09M - - -
Tax provision 0.22M -0.00M 0.00M 0.00M 0.00M
Interest income - - 0.15M 0.07M -
Net interest income 0.10M -0.09M 0.15M 0.07M 0.01M
Income tax expense 0.22M -0.00M - - -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 27.97M 12.23M 5.45M 12.32M 15.64M
Cost of revenue - 0.01M - - -
Total other income expense net -6.07M -0.12M 0.15M 0.07M -0.32M
Net income from continuing ops -34.26M -12.35M -5.30M -12.25M -15.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 90.17M 94.31M 4.17M 8.37M 15.78M
Intangible assets 68.99M 65.71M - - -
Other current assets 1.91M 1.70M 0.85M 1.34M 1.77M
Total liab 15.27M 30.03M 0.36M 1.04M 1.28M
Total stockholder equity 74.90M 64.28M 3.81M 7.33M 14.50M
Other current liab 2.24M 1.85M 0.25M 0.47M 0.92M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 74.41M 0.00M 0.00M 0.00M
Retained earnings -108.08M -73.82M -61.47M -56.17M -43.93M
Good will 12.40M 11.81M 0.00M - -
Other assets - -6.90M - - -
Cash 6.52M 14.85M 3.32M 7.03M 14.01M
Total current liabilities 3.06M 3.18M 0.36M 1.04M 1.28M
Net debt -6.36M 0.74M -3.32M -7.03M -14.01M
Short term debt 0.06M 0.10M - - -
Short long term debt total 0.16M 15.59M - - -
Other stockholder equity 183.56M 67.56M 65.28M 63.50M 58.43M
Total current assets 8.43M 16.54M 4.17M 8.37M 15.78M
Long term debt - 15.38M - - -
Accounts payable 0.76M 1.23M 0.11M 0.57M 0.35M
Accumulated other comprehensive income -0.59M -3.86M - - -
Non currrent assets other 0.16M 0.02M - - -
Non current assets total 81.74M 77.76M 0.00M 0.00M 0.00M
Capital lease obligations 0.16M 0.20M 0.00M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 3.76M 0.00M - -
Total cashflows from investing activities - 3.76M - - -
Net borrowings 3.00M 15.32M 0.00M - 0.00M
Total cash from financing activities 7.28M 16.70M 1.16M 4.49M -0.10M
Net income -34.26M -12.35M -5.30M -12.25M -15.96M
Change in cash -8.32M 11.53M -3.71M -6.98M -15.79M
Begin period cash flow 14.85M 3.32M 7.03M 14.01M 29.80M
End period cash flow 6.52M 14.85M 3.32M 7.03M 14.01M
Total cash from operating activities -15.62M -8.79M -4.87M -11.47M -15.69M
Issuance of capital stock 4.34M 1.38M 1.16M 4.49M -
Depreciation 0.00M 0.01M 0.00M - -
Dividends paid - - - - 0.00M
Sale purchase of stock 0.00M -0.00M 0.00M - -0.30M
Other cashflows from financing activities -0.05M -0.00M - - 0.20M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.13M -0.58M -0.19M 0.20M -0.05M
Stock based compensation 0.36M 0.48M 0.62M 0.58M 0.32M
Other non cash items 18.19M 3.65M - - -
Free cash flow -15.62M -8.79M -4.87M -11.47M -15.69M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
DWTX
Dogwood Therapeutics, Inc.		 0.24
23.08%		 1.28 - - - 0.71 0.22
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

44 Milton Avenue, Alpharetta, GA, United States, 30009

866 620 8655

https://dwtx.com

8

Name Title Year Born
Mr. Gregory Duncan Chairman & CEO 1965
Dr. William L. Pridgen M.D. Founder & Member of Scientific Advisory Board 1961
Ms. Angela Walsh CFO, Secretary & Treasurer 1967
Dr. R. Michael Gendreau M.D., Ph.D. Chief Medical Officer 1956
Mr. Ralph D. Grosswald M.P.H. Senior Vice President of Operations 1969
Ms. Carol Duffy Ph.D. Chief Scientific Advisor NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…